Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
22.75
+0.42 (1.88%)
At close: Sep 17, 2025, 4:00 PM EDT
22.25
-0.50 (-2.20%)
Pre-market: Sep 18, 2025, 4:24 AM EDT
HSDT Revenue
Helius Medical Technologies had revenue of $43.00K in the quarter ending June 30, 2025, a decrease of -76.37%. This brings the company's revenue in the last twelve months to $295.00K, down -50.34% year-over-year. In the year 2024, Helius Medical Technologies had annual revenue of $520.00K, down -19.25%.
Revenue (ttm)
$295.00K
Revenue Growth
-50.34%
P/S Ratio
2.81
Revenue / Employee
$14,048
Employees
21
Market Cap
24.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 520.00K | -124.00K | -19.25% |
Dec 31, 2023 | 644.00K | -143.00K | -18.17% |
Dec 31, 2022 | 787.00K | 265.00K | 50.77% |
Dec 31, 2021 | 522.00K | -139.00K | -21.03% |
Dec 31, 2020 | 661.00K | -835.00K | -55.82% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HSDT News
- 2 days ago - Inside Helius Medical's $500 Million Raise — And Its Solana Treasury Plans - Benzinga
- 2 days ago - Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company - PRNewsWire
- 2 months ago - Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements - GlobeNewsWire
- 2 months ago - Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 months ago - Helius Medical Technologies Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 3 months ago - Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire